Eli Lilly and Company

Charles V Jackson

Brian W Grinnell

Daniel C Howey

Gerald Floyd Smith

Robert T Shuman

Philip J Burck

Kenneth Dean Kurz

A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.

Methods for treating vascular disorders

Methods for treating vascular disorders using activated protein C

This application relates to a novel compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, processes and Intermediates for its preparation, pharmaceutical formulations comprising the novel compound of formula (I), and the use of the compound of formula (I) as an antithrombotic agent.

Antithrombotic compound

The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I domains of the native tissue plasminogen activator molecule.

Method of treating thromboembolic disorders by administration of

Growing community of inventors

Indianapolis, IN, United States of America

Charles V Jackson